Market Overview

UPDATE: Credit Suisse Initiates PDL Biopharma at Neutral on Dividend Continuity Questions

Related PDLI
Wall Street's M&A Chatter From October 31: Neos Therapeutics, Rockwell Automation-Emerson Electric, Charter
40 Biggest Movers From Yesterday
Neos Therapeutics: Cotempla Off To A Strong Start (Seeking Alpha)

Credit Suisse initiated coverage on PDL Biopharma (NASDAQ: PDLI) with a Neutral rating and a $6.50 price target.

Credit Suisse noted, "PDLI is unique among biotech companies, collecting royalties from some of the industry's biggest blockbuster antibodies and paying investors a high dividend, which we believe is fully reflected in its price. PDLI's value is primarily derived from Roche's antibody products, but increasingly it fortunes are tied to Eli Lilly's solanezumab. … PDLI is also leveraged to outperform Roche's products, for example Perjeta and T-DM1. We also expect an update to PDLI's plans to return capital to investors, potentially on its year-end conference call, which could include a special dividend."

PDL Biopharma closed at $7.83 on Monday.

Latest Ratings for PDLI

Dec 2016PiperJaffrayReinstatesOverweight
May 2013PiperJaffrayInitiates Coverage onNeutral
Mar 2013JP MorganMaintainsNeutral

View More Analyst Ratings for PDLI
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Initiation Intraday Update Analyst Ratings


Related Articles (PDLI)

View Comments and Join the Discussion!